Drug intelligence / Profile preview

IPX-A

Development stage: Preclinical
Lead developer: IpiNovyx Bio
Modality: Small Molecules

Overview

IPX-A is a dual proteasome inhibitor developed by IpiNovyx Bio for the treatment of inflammatory and autoimmune diseases, including ulcerative colitis. It targets both the standard (constitutive) proteasome and the immunoproteasome. In preclinical studies using human ulcerative colitis tissue explant cultures, IPX-A demonstrated the ability to reduce inflammatory signaling by significantly inhibiting the expression of key inflammatory biomarkers such as IL-8, IP-10, MIP-1b, IL-17, TNFb/LT-a, VEGF, and IL-10 [Sa1437].

Targets

26S proteasomeNeuraminidase

Beyond the preview

Go deeper on IPX-A.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IPX-A.